NTHI

CALABASAS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent corporate and clinical progress, including the upcoming presentation of data from its NEO100 and NEO212 programs at the Society for Neuro-Oncology Annual Meeting.

DENVER, Nov. 02, 2026 (GLOBE NEWSWIRE) --  ( 247MarketNews.com ) — In a market where the latest investment trends often dominate attention, NeOnc Technologies Holdings (NASDAQ: NTHI) is developing a story that could prove far more meaningful. The clinical-stage biopharmaceutical company is advancing potential treatments for some of the most difficult-to-treat brain cancers while building an ambitious clinical development strategy that could reach approximately 500 patients across 30 hospitals in three countries.

CALABASAS, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters on Friday, November 13, at the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), held November 12 to 15, 2026, at the Pennsylvania Convention Center in Philadelphia.

DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews.com ) — In a market where the latest whizbang trends often dominate investor attention, NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing something considerably more meaningful: advancing potential treatments for some of the most difficult-to-treat brain cancers while building a clinical development program that could eventually reach hundreds of patients internationally. Now, the company is putting some impressive numbers behind that ambition.

DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) — NeOnc Technologies Holdings (NASDAQ: NTHI) is setting its sights on a substantially larger international clinical effort, outlining plans for a trial targeting approximately 500 patients across 30 hospitals in three countries during a discussion on Health Uncensored with Dr. Drew, on Fox Business Network. The proposed expansion brings fresh attention to NeOnc's effort to address one of brain cancer treatment's toughest challenges: delivering potential therapies into the brain.

DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) cleared several key resistance levels, on strong trading volume, delivering a potentially important technical signal for a stock that recently tested lows near $2.50. The breakout marks a significant development from its recent chart snapshots.

CALABASAS, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it will be featured on Health Uncensored with Dr. Drew, a national health television series hosted by Dr. Drew Pinsky, in a segment on non-invasive approaches to delivering investigational therapies to brain tumors.

Compassionate care for children in Abu Dhabi, a new research MoU and a senior banking appointment add momentum to NeOnc's development story Houston, Texas--(Newsfile Corp. - October 21, 2026) - As NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) prepares for an upcoming FDA meeting, its work in Abu Dhabi is bringing that human side of biotechnology into focus. Technology today can feel like magic.

DENVER, Oct. 21, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) — “I wish someone had told me about that company.” That is a familiar reaction when a stock attracts attention after investors have spent months overlooking it.

Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu Dhabi Two children in Abu Dhabi are receiving investigational NEO100 through NeOnc's Compassionate Care program, with a third expected this week CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 21, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it has signed a Memorandum of Understanding (MoU) with the Department of Health – Abu Dhabi (DoH) to cooperate on the development of research and clinical capability in oncology and central nervous system therapeutics in the Emirate of Abu Dhabi.